AU2006272937A1 - Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders - Google Patents
Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders Download PDFInfo
- Publication number
- AU2006272937A1 AU2006272937A1 AU2006272937A AU2006272937A AU2006272937A1 AU 2006272937 A1 AU2006272937 A1 AU 2006272937A1 AU 2006272937 A AU2006272937 A AU 2006272937A AU 2006272937 A AU2006272937 A AU 2006272937A AU 2006272937 A1 AU2006272937 A1 AU 2006272937A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- group
- polypeptide
- patient
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 27
- 208000023275 Autoimmune disease Diseases 0.000 title claims 7
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 title 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 title 1
- 102100020990 Interferon lambda-1 Human genes 0.000 title 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims 38
- 238000000034 method Methods 0.000 claims 33
- 201000011510 cancer Diseases 0.000 claims 26
- 208000034578 Multiple myelomas Diseases 0.000 claims 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 14
- 208000024891 symptom Diseases 0.000 claims 14
- 238000009472 formulation Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 12
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 12
- 208000003950 B-cell lymphoma Diseases 0.000 claims 12
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 12
- 206010005949 Bone cancer Diseases 0.000 claims 12
- 208000018084 Bone neoplasm Diseases 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- 206010008342 Cervix carcinoma Diseases 0.000 claims 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 12
- 206010009944 Colon cancer Diseases 0.000 claims 12
- 206010018338 Glioma Diseases 0.000 claims 12
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 12
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 12
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 12
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 12
- 206010033128 Ovarian cancer Diseases 0.000 claims 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 12
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 12
- 206010060862 Prostate cancer Diseases 0.000 claims 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 12
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 12
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 12
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 12
- 206010057644 Testis cancer Diseases 0.000 claims 12
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 12
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 12
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 12
- 201000010881 cervical cancer Diseases 0.000 claims 12
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 12
- 208000029742 colonic neoplasm Diseases 0.000 claims 12
- 206010017758 gastric cancer Diseases 0.000 claims 12
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 12
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 12
- 201000005202 lung cancer Diseases 0.000 claims 12
- 208000020816 lung neoplasm Diseases 0.000 claims 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 12
- 201000001441 melanoma Diseases 0.000 claims 12
- 201000002528 pancreatic cancer Diseases 0.000 claims 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 12
- 201000011549 stomach cancer Diseases 0.000 claims 12
- 201000003120 testicular cancer Diseases 0.000 claims 12
- 201000002510 thyroid cancer Diseases 0.000 claims 12
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 12
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000008961 swelling Effects 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010014020 Ear pain Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010048393 Multiple sclerosis relapse Diseases 0.000 claims 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000007176 earache Diseases 0.000 claims 2
- 208000001780 epistaxis Diseases 0.000 claims 2
- 210000004013 groin Anatomy 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000028755 loss of height Diseases 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 206010029410 night sweats Diseases 0.000 claims 2
- 230000036565 night sweats Effects 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 230000009747 swallowing Effects 0.000 claims 2
- 208000016255 tiredness Diseases 0.000 claims 2
- 230000003867 tiredness Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 229920001427 mPEG Polymers 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70095105P | 2005-07-20 | 2005-07-20 | |
| US60/700,951 | 2005-07-20 | ||
| US77126006P | 2006-02-08 | 2006-02-08 | |
| US60/771,260 | 2006-02-08 | ||
| PCT/US2006/028106 WO2007013944A2 (en) | 2005-07-20 | 2006-07-20 | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2006272937A1 true AU2006272937A1 (en) | 2007-02-01 |
| AU2006272937A8 AU2006272937A8 (en) | 2008-02-28 |
Family
ID=37683787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006272937A Abandoned AU2006272937A1 (en) | 2005-07-20 | 2006-07-20 | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20070020227A1 (enExample) |
| EP (1) | EP1909821A2 (enExample) |
| JP (1) | JP4987001B2 (enExample) |
| AU (1) | AU2006272937A1 (enExample) |
| CA (1) | CA2616004A1 (enExample) |
| IL (1) | IL188357A0 (enExample) |
| WO (1) | WO2007013944A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271786A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Interferon-like protein zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| EP2251353B1 (en) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| EP1912668A2 (en) * | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| AU2006272937A1 (en) * | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1931704B1 (en) | 2005-10-04 | 2010-12-15 | ZymoGenetics, L.L.C. | Production and purification of il-29 |
| JP2009115776A (ja) * | 2007-07-11 | 2009-05-28 | Ngk Spark Plug Co Ltd | アンモニアガスセンサ |
| JP5083898B2 (ja) * | 2007-07-11 | 2012-11-28 | 日本特殊陶業株式会社 | アンモニアガスセンサ |
| RU2496514C2 (ru) * | 2008-06-05 | 2013-10-27 | Займоджинетикс, Инк. | Применение пэгилированных интерферонов типа iii для лечения гепатита с |
| US20100316608A1 (en) * | 2009-06-15 | 2010-12-16 | Vijayaprakash Suppiah | Method of Determining A Response To Treatment With Immunomodulatory Composition |
| FR2975185A1 (fr) * | 2011-05-12 | 2012-11-16 | Univ Claude Bernard Lyon | Procede de determination in vitro de la presence d'une sclerose en plaques |
| CN104045704B (zh) * | 2013-03-11 | 2016-08-10 | 中国医学科学院基础医学研究所 | PEG化重组人IFN-λ1、其制备方法和用途 |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN103923209B (zh) * | 2014-05-13 | 2016-06-22 | 北京凯因科技股份有限公司 | 一种Lambda干扰素突变体及聚乙二醇衍生物 |
| CN105085658B (zh) * | 2014-05-14 | 2019-12-24 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体及聚乙二醇衍生物 |
| DE102015001902A1 (de) * | 2015-02-18 | 2016-08-18 | Continental Reifen Deutschland Gmbh | Verfahren zur Verbesserung der Haftung zwischen einem Verstärkungselement und einem elastomeren Matrixmaterial |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| KR20180110127A (ko) | 2016-02-19 | 2018-10-08 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| JP2019531729A (ja) * | 2016-09-30 | 2019-11-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 変異体ｉｉｉ型インターフェロン及びシンセカイン |
| US20220378878A1 (en) * | 2019-12-20 | 2022-12-01 | The Council Of The Queensland Institute Of Medical Research | Treatment of gastrointestinal disease |
| KR102226826B1 (ko) * | 2020-08-06 | 2021-03-11 | 주식회사 휴벳바이오 | 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI86558C (fi) | 1980-01-08 | 1992-09-10 | Biogen Inc | Dna- sekvenser, rekombinant-dna- molekyler och foerfaranden foer framstaellning av humant interferon av -typ och val av dna-sekvensen. |
| US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6468776B1 (en) * | 2000-03-03 | 2002-10-22 | Zymogenetics, Inc. | Human serine protease |
| AU2001271589A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Mammalian secreted proteins |
| AU2001271786A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Interferon-like protein zcyto21 |
| EP2298789B1 (en) | 2000-09-08 | 2012-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
| US7038032B2 (en) * | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| CN100482684C (zh) * | 2001-04-20 | 2009-04-29 | 津莫吉尼蒂克斯公司 | 细胞因子蛋白质家族 |
| PL373008A1 (en) * | 2001-05-10 | 2005-08-08 | Immunex Corporation | Cytokine polypeptides |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| BR0309401A (pt) * | 2002-04-19 | 2007-02-21 | Zymogenetics Inc | polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo |
| EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| EP2251353B1 (en) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| CA2558829C (en) | 2004-04-02 | 2014-03-11 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| AU2005266892B2 (en) * | 2004-07-29 | 2011-03-03 | Bristol-Myers Squibb Company | Use of IL-28 and IL-29 to treat cancer and autoimmune disorders |
| CN1305902C (zh) | 2004-11-25 | 2007-03-21 | 汕头大学医学院 | 一种人白细胞介素29的生产方法及重组il－29工程菌 |
| AU2006272937A1 (en) * | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1912668A2 (en) * | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| EP1931704B1 (en) * | 2005-10-04 | 2010-12-15 | ZymoGenetics, L.L.C. | Production and purification of il-29 |
-
2006
- 2006-07-20 AU AU2006272937A patent/AU2006272937A1/en not_active Abandoned
- 2006-07-20 CA CA002616004A patent/CA2616004A1/en not_active Abandoned
- 2006-07-20 JP JP2008522947A patent/JP4987001B2/ja active Active
- 2006-07-20 US US11/489,894 patent/US20070020227A1/en not_active Abandoned
- 2006-07-20 WO PCT/US2006/028106 patent/WO2007013944A2/en not_active Ceased
- 2006-07-20 EP EP06787912A patent/EP1909821A2/en not_active Withdrawn
-
2007
- 2007-12-24 IL IL188357A patent/IL188357A0/en unknown
-
2009
- 2009-11-02 US US12/611,067 patent/US20100298230A1/en not_active Abandoned
-
2011
- 2011-03-07 US US13/042,210 patent/US8313739B2/en active Active
-
2012
- 2012-04-05 US US13/440,066 patent/US20120251488A1/en not_active Abandoned
-
2013
- 2013-08-22 US US13/973,127 patent/US20140044676A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2616004A1 (en) | 2007-02-01 |
| WO2007013944A3 (en) | 2007-05-18 |
| WO2007013944A2 (en) | 2007-02-01 |
| US20100298230A1 (en) | 2010-11-25 |
| US20120251488A1 (en) | 2012-10-04 |
| IL188357A0 (en) | 2008-04-13 |
| JP4987001B2 (ja) | 2012-07-25 |
| US8313739B2 (en) | 2012-11-20 |
| US20140044676A1 (en) | 2014-02-13 |
| US20070020227A1 (en) | 2007-01-25 |
| EP1909821A2 (en) | 2008-04-16 |
| JP2009502800A (ja) | 2009-01-29 |
| AU2006272937A8 (en) | 2008-02-28 |
| US20110177024A1 (en) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006272937A1 (en) | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders | |
| Banks et al. | Interleukin 12: a new clinical player in cytokine therapy | |
| IL108053A0 (en) | Lamotrigine in the treatment of neurological lesions associated with trauma | |
| EP0565587A4 (en) | The effect of n,n,n-trimethylsphingosine on protein kinase-c activity; melanoma cell growth -i(in vitro); metastatic potential -i(in vivo) and human platelet aggregation | |
| AR008378A1 (es) | Conjudados de interferon | |
| MXPA04005266A (es) | Inmunocitocinas con selectividad modulada. | |
| Shalit et al. | Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G‐CSF in a murine model of cyclophosphamide‐induced leukopenia | |
| NO942851L (no) | Nytt cytokin som binder CD30 | |
| EP1401870A4 (en) | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) | |
| EP0725641A4 (enExample) | ||
| Daenen et al. | Successful chemotherapy with deoxycoformycin in adult T‐cell lymphoma‐leukaemia | |
| NZ259584A (en) | Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells | |
| Beran et al. | Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells | |
| Sarna et al. | Phase I study of recombinant beta ser 17 interferon in the treatment of cancer. | |
| JP3496937B2 (ja) | コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物 | |
| Frampton et al. | Lenograstim: a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings | |
| Vidriales et al. | Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution | |
| GR3020330T3 (en) | Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds. | |
| Kobayashi et al. | MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance | |
| Eton et al. | A Phase II study of “decrescendo” interleukin‐2 plus interferon‐α‐2a in patients with progressive metastatic melanoma after chemotherapy | |
| Teichmann et al. | Induction of lymphokine-activated killer cells against human leukemia cells in vitro | |
| Wells et al. | Interferon-αnl in Children with Recurrent Acute Lymphocytic Leukemia: A Phase I Study of Pharmacokinetics and Tolerance | |
| Sertoli et al. | Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α2a and tamoxifen in metastatic melanoma | |
| Weide et al. | Successful treatment of neutropenia in T-LGL leukemia (Tγ-lymphocytosis) with granulocyte colony-stimulating factor | |
| BR9809159A (pt) | Composição farmacêutica contendo uscaridina ou seus análogos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 22, NO 6, PAGE(S) 676 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME ZYMOGENETICS, INC., APPLICATION NO. 2006272937, UNDER INID (71) CORRECTED THE APPLICANT NAM E TO ZYMOGENETICS, INC. |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: BRISTOL-MYERS SQUIBB COMPANY; ZYMOGENETICS, INC. Free format text: FORMER APPLICANT(S): ZYMOGENETICS, INC. |
|
| TH | Corrigenda |
Free format text: IN VOL 23, NO 39, PAGE(S) 10380 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2006 DELETE ALL REFERENCE TO APPLICATION NO. 2006272937 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |